# A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

> **NCT06038396** · PHASE1,PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** RC118
- **DRUG:** Toripalimab
- **DRUG:** RC148

## Key facts

- **NCT ID:** NCT06038396
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-03
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-08-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06038396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06038396, "A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06038396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*